Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.13B P/E - EPS this Y -6.00% Ern Qtrly Grth -
Income -460.47M Forward P/E -9.21 EPS next Y -3.20% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 11.80 EPS next 5Y - 52W High Chg -36.00%
Recommedations 3.00 Quick Ratio 10.12 Shares Outstanding 182.20M 52W Low Chg 16.00%
Insider Own 15.33% ROA -29.79% Shares Float 77.82M Beta 1.41
Inst Own 85.12% ROE -92.45% Shares Shorted/Prior 5.98M/6.36M Price 26.33
Gross Margin - Profit Margin - Avg. Volume 520,117 Target Price 43.40
Oper. Margin - Earnings Date Oct 30 Volume 2,422,080 Change -14.09%
About Cerevel Therapeutics Holdings,

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Sell 41.45 8,000 331,600 24,663 12/27/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Option 3.5 8,000 28,000 32,663 12/27/23
Bodenrader Mark See Remarks See Remarks Dec 19 Sell 41.42 7,889 326,762 17,724 12/21/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 19 Sell 41.42 6,256 259,124 24,663 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 19 Sell 41.42 7,072 292,922 7,237 12/21/23
Sanchez Ramiro Chief Medical Office.. Chief Medical Officer Dec 19 Sell 41.42 10,152 420,496 14,673 12/21/23
ALTSCHULLER Susan Chief Financial Offi.. Chief Financial Officer Dec 19 Sell 41.42 13,808 571,927 16,913 12/21/23
Tregoning Kathleen See Remarks See Remarks Dec 19 Sell 41.42 6,288 260,449 7,516 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Sell 38.19 17,500 668,325 513 12/07/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Option 13.17 17,500 230,475 10,513 12/07/23
COLES N ANTHONY Director Director Nov 07 Sell 25.09 27,176 681,846 2,704 11/09/23
COLES N ANTHONY Director Director Nov 07 Option 3.5 27,176 95,116 2,804 11/09/23
COLES N ANTHONY Director Director Nov 02 Sell 25.31 100,000 2,531,000 2,704 11/06/23
COLES N ANTHONY Director Director Nov 02 Option 3.5 100,000 350,000 64,105 11/06/23
PERCEPTIVE ADVISORS LLC Director Director Oct 16 Buy 22.81 876,808 19,999,990 10,794,876 10/17/23
Renaud Ronald C JR President & CEO President & CEO Aug 03 Buy 23.9552 83,857 2,008,811 83,857 08/07/23
Burgess Paul D. See Remarks See Remarks Aug 04 Buy 22.9339 21,880 501,794 21,880 08/07/23
COLES N ANTHONY Director Director Jul 11 Sell 30.03 50,000 1,501,500 2,704 07/13/23
COLES N ANTHONY Director Director Jul 11 Option 3.5 50,000 175,000 52,704 07/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Sell 32.6 50,000 1,630,000 2,704 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Option 3.5 50,000 175,000 52,704 06/05/23
Bodenrader Mark See Remarks See Remarks Jun 01 Sell 32.95 1,895 62,440 5,522 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Sell 25.06 50,000 1,253,000 2,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Option 3.5 50,000 175,000 52,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Sell 33.31 50,000 1,665,500 2,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Option 3.5 50,000 175,000 52,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Sell 30.33 50,000 1,516,500 2,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Option 3.5 50,000 175,000 52,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Option 3.5 50,000 175,000 52,704 12/13/22
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Sell 26.86 50,000 1,343,000 2,704 12/13/22
PERCEPTIVE ADVISORS LLC Director Director Aug 16 Buy 35.00 1,425,000 49,875,000 6,511,727 08/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Option 3.5 30,000 105,000 12,704 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Sell 35.13 30,000 1,053,900 2,704 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Option 13.17 10,000 131,700 10,000 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Sell 40 10,000 400,000 08/09/22
Ceesay Abraham President President Aug 05 Sell 36.58 57,635 2,108,288 08/09/22
Ceesay Abraham President President Aug 05 Option 13.17 57,635 759,053 19,211 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Option 3.5 26,105 91,368 3,809 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 31.25 26,105 815,781 2,704 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Option 3.5 45,000 157,500 46,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Sell 34.65 45,000 1,559,250 1,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Option 3.5 45,000 157,500 21,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Sell 31.25 45,000 1,406,250 1,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Option 3.5 25,000 87,500 26,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Sell 30 25,000 750,000 1,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Option 3.5 37,700 131,950 9,102 12/17/21
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Sell 31.67 37,700 1,193,959 1,980 12/17/21
PERCEPTIVE ADVISORS LLC Director Director Aug 25 Buy 27.36 175,585 4,804,006 5,018,680 08/25/21